Management

Nick joined Intercytex as Chief Executive Officer in January 2005 having been a Non-Executive Director of the company since it was founded, and brings over 20 years of experience in commercialising biotechnology products. He was previously Chief Business Officer and a Board Director of Acambis plc (vaccines) which he joined in 1994. He was responsible for all commercial activities including IP management, licensing, corporate development, mergers/acquisitions and sales and marketing. In addition, he played a key role in the company’s flotation on the London Stock Exchange in 1995.

Prior to Acambis he worked for Porton International Ltd (biologicals) where he managed IP and commercial agreements with the company’s collaborators. Before Porton he worked for The PA Consultancy Group where he was a founder member of the Biotechnology Group in which he participated in over 50 European and international assignments. He started his business career with Unilever Research Ltd (consumer goods) as a chemical and biochemical engineer. Nick has a BSc in biochemistry from the University College of Wales, an MSc in biochemical engineering from University College, London and an MSc in the Management of Intellectual Property from QMW, London.

Max joined Intercytex as Chief Financial Officer in September 2008. Previously he was a consultant for Fusion IP plc (an investor in science and technology) and Managing Director of ING Equity Markets where he managed a team of analysts and a specialist sales force covering the European pharmaceutical, biotechnology and healthcare sectors. Prior to ING, he was a pharmaceutical analyst at Robert Fleming Securities. Max started his industry career as financial controller for Onyx Pharmaceuticals, a US-quoted drug development company, where he was integral to its successful listing on NASDAQ. Max has a BSc (Hons) in microbiology from the University of Kent, and qualified as a Chartered Accountant with Arthur Andersen.

Paul founded Intercytex in 1999 and is its Chief Scientific Officer. He has over 17 years of experience in the commercial development of cell therapies. Prior to founding Intercytex, he was VP Research at Organogenesis Inc. He joined the founders in 1987 as a staff scientist researching into collagen as part of the wound repair stimulant programme Apligraf® and he was later instrumental in its development, manufacture and methods of shipping. He is a principal inventor on several patents related to various regenerative medicines. Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.

John joined Intercytex as VP Clinical and Regulatory Affairs in September 2005 with over 20 years of experience in the clinical development of vaccines and biological products. Previously, he held the position of Medical Director at a number of leading biotechnology companies including Microscience plc, Xenova Group plc, Cantab Pharmaceuticals plc and Merieux UK.

John graduated in medicine from the Royal College of Surgeons in Ireland and prior to his career in industry, he practised hospital medicine for a number of years in the National Health Service (UK). John has contributed to numerous publications, presentations, technical committees and lectures.

John was elected a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK) in 1999 and is a Fellow of the Royal Society of Medicine and the Medical Society of London. He is also a Member of the British Association of Pharmaceutical Physicians, the British Medical Association and the Medico-Legal Society.

John joined Intercytex in April 2007 with over 20 years of experience in the production of biologicals, the management of GMP facilities, QA/QC and regulatory compliance. He was previously Director of GMP Manufacturing Operations at Cobra Biomanufacturing plc, a contract manufacturer of clinical grade proteins, DNA and viruses. Prior to Cobra he was an independent consultant to the industry, VP of Technical R&D and Manufacturing at Centelion (formerly Gencell, a Paris-based, French biopharmaceutical/gene therapy company spun out from Aventis), VP Operations at Genzyme Corporation (UK subsidiary of a US biotechnology company), Fermentation Manager at Fermentech Ltd (a private fermentation facility) and he started his career as a research scientist at Technoferm Developments Ltd (Porton Down).

John has a BSc in Applied Biology and a PhD in enzyme biosynthesis.